Synergistic antitumor effects of Escherichia coli maltose binding protein and Bacillus Calmette-Guerin in a mouse lung carcinoma model

Immunology Letters

Volumn 136, Issue 1, 2011, Pages 108-113

  Zhang, Qingyong ^a   Ni, Weihua ^a   Zhao, Xiaoxia ^a   Wang, Fengli ^a   Gao, Zhuo ^a   Tai, Guixiang ^a  

^a Basic Medical College   (China)

Author keywords

Antitumor effects; BCG; Macrophages; MBP; NK cells; Th1 cells

Indexed keywords

BCG VACCINE; MALTOSE BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; ESCHERICHIA COLI; FEMALE; LUNG CARCINOMA; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR GROWTH;

ANIMALS; BACILLUS; CELL PROLIFERATION; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; FEMALE; IMMUNIZATION; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MALTOSE-BINDING PROTEINS; MICE; MICE, INBRED C57BL; MYCOBACTERIUM BOVIS;

EID: 79952311369     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2010.12.005     Document Type: Article

References (26)

1. Riggs P. Expression and purification of recombinant proteins by fusion to maltose-binding protein. Mol Biotechnol 2000, 15(1):51-63.
2. Kang Q.Z., Duan G.C., Fan Q.T., Xi Y.L. Fusion expression of Helicobacter pylori neutrophil-activating protein in E. coli. World J Gastroenterol 2005, 11(3):454-456.
3. Witteveldt J., Vlak J.M., van Hulten M.C. Protection of Penaeus monodon against white spot syndrome virus using a WSSV subunit vaccine. Fish Shellfish Immunol 2004, 16(5):571-579.
4. Simmons M., Murphy G.S., Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 2001, 65(2):159-161.
5. Simmons M., Murphy G.S., Kochel T., Raviprakash K., Hayes C.G. Characterization of antibody responses to combinations of a dengue-2 DNA and dengue-2 recombinant subunit vaccine. Am J Trop Med Hyg 2001, 65(5):420-426.
6. Fernandez S., Palmer D.R., Simmons M., Sun P., Bisbing J., McClain S., et al. Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells. Infect Immun 2007, 75(3):1359-1363.
7. Zhao X.X., Ma J.C., Fang F., Zhou J., Song X.M., Liu Z.H., et al. Effect of Escherichia coli maltose binding protein on mouse Th1 cell activation. Chin J Immunol 2009, 25(6):504-507.
8. Song X.M., Fang F., Ma J.C., Zhao X.X., Tai G.X. A MUC1-MBP induces antitumor effect in subcutaneous transplantation mouse model of human breast cancer. Chin J Immunol 2010, 26:428-432.
9. Haanen J.B., de Waal Malefijt R., Res P.C., Kraakman E.M., Ottenhoff T.H., de Vries R.R., et al. Selection of a human T helper type 1-like T cell subset by mycobacteria. J Exp Med 1991, 174(3):583-592.
10. Orme I.M. Immunity to mycobacteria. Curr Opin Immunol 1993, 5(4):497-502.
11. Paul W.E., Seder R.A. Lymphocyte responses and cytokines. Cell 1994, 76(2):241-251.
12. Sanchez Olivas M.A., Valencia Zavala M.P., Montes Montes J., Sanchez Olivas J.A., Flores Mendez I. Immunology and BCG therapeutics. Rev Alerg Mex 2008, 55(4):153-163.
13. Kirkwood J.M., Tarhini A.A., Panelli M.C., Moschos S.J., Zarour H.M., Butterfield L.H., et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008, 26(20):3445-3455.
14. Raez L.E., Fein S., Podack E.R. Lung cancer immunotherapy. Clin Med Res 2005, 3(4):221-228.
15. You Z., Hester J., Rollins L., Spagnoli G.C., van der Bruggen P., Chen S.Y. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses. Cancer Res 2001, 61(1):197-205.
16. Zhou J., Tai G., Liu H., Ge J., Feng Y., Chen F., et al. Activin A down-regulates the phagocytosis of lipopolysaccharide-activated mouse peritoneal macrophages in vitro and in vivo. Cell Immunol 2009, 255(1-2):69-75.
17. Greager J.A., Culberson G., Manning B., Das Cupta T.K. Chemotherapy, BCG, and serum from tumor-bearing mice: comparative effects on growth and spread of mouse Lewis lung cancer. Arch Surg 1975, 110(8):901-902.
18. Martino A., Casetti R., Poccia F. Enhancement of BCG-induced Th1 immune response through Vgamma9Vdelta2 T cell activation with non-peptidic drugs. Vaccine 2007, 25(6):1023-1029.
19. Young H.A., Hardy K.J. Role of interferon-gamma in immune cell regulation. J Leukoc Biol 1995, 58(4):373-381.
20. Yu T.K., Caudell E.G., Smid C., Grimm E.A. IL-2 activation of NK cells: involvement of MKK1/2/ERK but not p38 kinase pathway. J Immunol 2000, 164(12):6244-6251.
21. Boehm U., Klamp T., Groot M., Howard J.C. Cellular responses to interferon-gamma. Annu Rev Immunol 1997, 15:749-795.
22. Asano Y., Kaneda K., Hiragushi J., Tsuchida T., Higashino K. The tumor-bearing state induces augmented responses of organ-associated lymphocytes to high-dose interleukin-2 therapy in mice. Cancer Immunol Immunother 1997, 45(2):63-70.
23. Moretta L., Bottino C., Cantoni C., Mingari M.C., Moretta A. Human natural killer cell function and receptors. Curr Opin Pharmacol 2001, 1(4):387-391.
24. Zhang J., Sun R., Wei H., Tian Z. Antitumor effects of recombinant human prolactin in human adenocarcinoma-bearing SCID mice with human NK cell xenograft. Int Immunopharmacol 2005, 5(2):417-425.
25. Mills C.D., Kincaid K., Alt J.M., Heilman M.J., Hill A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000, 164(12):6166-6173.
26. Van Ginderachter J.A., Movahedi K., Hassanzadeh Ghassabeh G., Meerschaut S., Beschin A., Raes G., et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 2006, 211(6-8):487-501.